Renin-angiotensin system inhibitors for prevention of new-onset atrial fibrillation

Connecticut Medicine

Volumn 71, Issue 4, 2007, Pages 205-209

  Baker, William L ^a   White, C Michael ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DRUG EFFECT; HEART ATRIUM FIBRILLATION; HUMAN; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RENIN-ANGIOTENSIN SYSTEM;

EID: 34249314411     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Fuster V, Ryden LE, Cannom DS, et al: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48:e149 -246.
2. Go AS, Hylek EM, Phillips KA, et al: Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-5.
3. McEwan PE, Gray GA, Sherry L, et al: Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98:2765-73.
4. Xiao H, Fuchs S, Campbell DJ, et al: Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004; 165:1019-32.
5. Goette A, Staack T, Rocken C, et al: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35:1669-7.
6. Verheule S, Sato T, Everett T, et al: Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1. Circ Res 2004; 94:1458-65.
7. Dostal DE: Regulation of cardiac collagen: Angiotensin and cross-talk with local growth factors. Hypertension 2001; 37:841-4.
8. Li D, Shinagawa K, Pang L, et al: Effects of angiotensin-converting enzyme inhibition on the development of atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104:2608-14.
9. Nakashima H, Kumagai K, Urata H, et al: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101:2612-7.
10. Dobrev D, Ravens U. Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res Cardiol 2003;98:137-48.
11. Gassanov N, Brandt MC, Michels G, et al: Angiotensin-II induced changes of calcium sparks and ionic currents in human atrial myocytes: Potential role of early remodeling in atrial fibrillation. Cell Calcium 2006; 39:175-86.
12. Wang J, Wang Y, Zhu Z, et al: Diverse effects of long-term treatment with imidapril and irbesartan on cell growth signal, apoptosis and collagen type I expression in the left ventricle of spontaneously hypertensive rats. Life Sciences 2004; 75:407-20.
13. Boldt A, Scholl A, Garbade J, et al: ACE-inhibition treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 2006; 101:261-7.
14. Boldt A, Wetzel U, Weigl J, et al: Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003; 42:1785-92.
15. Zankov DP, Omatsu-Kanbe MO, Isono T, et al: Angiotensin II potentiates the slow componenet of delayed rectifier K+ current via the ATI receptor in guinea pig atrial myocytes. Circulation 2006; 113:1278-86.
16. Shibata R, Nakao K, Fukai S, et al: Angiotensin-converting enzyme inhibitor suppresses the incidence of prolonged and fractionated right atrial electrograms. PACE 2006; 29:164-70.
17. Engelmann MDM, Svendsen JH: Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26:2083-92.
18. Anderson JL, Maycock CAA, Lappe DL, et al: Frequency of elevation of c-reactive protein in atrial fibrillation. Am J Cardiol 2004;94:1255-9.
19. Brasier AR, Recinos A, Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22:1257-66.
20. Cunha C, Tham DM, Martin-McNulty B, et al: Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005; 178:9-17.
21. Koulouris S, Symeonides P, Triantafyllou K, et al: Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity c-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes melliltus. Am J Cardiol 2005; 95:1386-8.
22. L'Allier PL, Ducharme A, Keller PF, et al: Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44:159-64.
23. Hansson L, Lindholm LH, Ekbom T, et al: Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-6.
24. Hansson L, Lindholm, Niskanen, et al: Effect of angiotensin-converting- enzyme inhibition compared with conventional theapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353:611-6.
25. Vermes E, Tardig JC, Bourassa MG, et al: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003; 107:2926-31.
26. Pedersen OD, Bagger H, Kober L, et al: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376-80.
27. Pizzetti F, Turazza FM, Franzosi MG, et al: Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: The GISSI-3 data. Heart 2001; 86:527-32.
28. Healey JS, Baranchuk A, Crystal E, et al: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45:1832-9.
29. Anand K, Mooss AN, Hee T, et al: Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152:217-22.
30. Kalus JS, Coleman CI, White CM: The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 2006; 46:21-8.
31. Wachtell K, Lehto M, Gerdts E, et al: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-9.
32. Maggioni AP, Latini R, Carson PE, et al: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149:548-57.
33. DFucharme A, Swedberg K, Pfeffer MA, et al: Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 2006; 152:86-92.